Peptide Receptor Radionuclide Therapy (PRRT) Lu-177

Similar documents
In-Patient Radioactive Iodine ( 131 I) Treatment

UW MEDICINE PATIENT EDUCATION. Treating Hyperthyroidism with Radioactive Iodine. How to prepare DRAFT. What is radioactive iodine treatment?

I131 Radioactive Iodine to Treat Thyroid Cancer

I131 Radioactive Iodine to Treat Thyroid Cancer

ORAL CHEMOTHERAPY EDUCATION

ORAL CHEMOTHERAPY EDUCATION

High Dose Radioactive Iodine (I-131) Therapy for Treatment of Thyroid Cancer for Out-Patients

Sorafenib (Nexavar ) ( sor-af-e-nib )

Patient Guide Radioiodine (Iodine-131) Therapy Radiation Safety Office

AC: Doxorubicin and Cyclophosphamide

TC: Docetaxel and Cyclophosphamide

Gemcitabine and Cisplatin

ORAL CHEMOTHERAPY EDUCATION

FEC: Fluorouracil, Epirubicin and Cyclophosphamide

Trastuzumab and Lapatinib

Paclitaxel and Carboplatin

CMF: Cyclophosphamide, Methotrexate and Fluorouracil

ORAL CHEMOTHERAPY EDUCATION

Imatinib (Gleevec ) ( eye-mat-eh-nib )

Infection Control Blood Borne Pathogens. Pines Behavioral Health

Darren Lackan, MD Chris Bajaj, DO Anjanette Tan, MD Christopher Hudak, MD Stefanie Addington, MD

TCH: Docetaxel, Carboplatin and Trastuzumab

Everolimus (Afinitor )

Oral Systemic Therapy

ORAL CHEMOTHERAPY EDUCATION

Dabrafenib (Tafinlar )

Eltrombopag (Promacta )

UW MEDICINE PATIENT EDUCATION. PCV Treatment Chemotherapy for brain tumors DRAFT. PCV is a type of chemotherapy (chemo) treatment for brain

Midostaurin (Rydapt )

Oral Systemic Therapy

Lu 177-Dotatate (Lutathera) Therapy Information

ORAL CHEMOTHERAPY EDUCATION

Neuroendocrine Tumor Imaging

Lenvatinib (Lenvima ) ( len-va-ti-nib )

Ibrutinib (Imbruvica )

What is Capecitabine (ka-pe-site-a-been) and how does it work?

May Safety Subject. Bloodborne Pathogens

Infection Control Handout

Capecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions

CVD: Cisplatin, Vinblastine, and Dacarbazine

Exemestane and Everolimus

What is Abemaciclib (ABEM-a-si-clib) and how does it work?

CHEROKEE COUNTY SCHOOL DISTRICT

21. Getting Tested for HIV

Acute Hepatitis B Fact Sheet

At the end of this session, the participants will be able to:

Supervisors, Department Heads and Principals will:

PART I. RADIONUCLIDE THERAPY WITH I-131 SODIUM IODIDE: PATIENT & DOSE ADMINISTRATOR PRECAUTIONS; ADMINISTRATION METHODS

Home Care for Your Nephrostomy Catheter - The James

Hazardous Drug Safety

ORAL CHEMOTHERAPY EDUCATION

Hepatitis B is a virus that attacks the liver. It is highly infectious. Hepatitis B is transmitted primarily

ORAL CHEMOTHERAPY EDUCATION

Patient Guide to Radioiodine Treatment For Thyrotoxicosis (Overactive Thyroid Gland or Hyperthyroidism)

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

High Dose Radioactive Iodine (I-131) Therapy for Treatment of Thyroid Cancer

Capecitabine and Lapatinib

BLOODBORNE PATHOGENS Online Training for Buncombe County Public School Employees

ORAL CHEMOTHERAPY EDUCATION

Patient & Family Guide. Norovirus. Aussi disponible en français : Norovirus (FF )

Zevalin (Yttrium - 90 Ibritumomab Tiuxetan) for Transplant Patients

ORAL CHEMOTHERAPY EDUCATION

Daunorubicin daw-no-roo-bih-sin

What is a Bloodborne Disease?

Iodine ablation treatment frequently asked questions

ORAL CHEMOTHERAPY EDUCATION

Urinary Tract Infections

Miami Dade County Public Schools

Table of Seasonal Influenza Vaccine Total Doses Distributed

a patient s guide Radioiodine therapy for benign (non-cancerous) thyroid disease Patient Information Series PI 14

Universal Precautions

Orion ISO Universal Precautions Employee Training Module

CMC Annual Review of BLOODBORNE DISEASES. Prevention of Transmission for School Staff

May Safety Subject. Bloodborne Pathogens

Medication Guide Fentanyl transdermal system, CII Rx Only Fentanyl transdermal system is: A strong prescription pain medicine that contains an opioid

Bloodborne Pathogens Training For School Personnel

The facts you need to know

Robotic Prostatectomy - After Surgery

ORAL CHEMOTHERAPY EDUCATION

ORAL CHEMOTHERAPY EDUCATION

ORAL CHEMOTHERAPY EDUCATION

Infections of the Urine System 366 What causes bladder and kidney infections? 366 Signs and treatment 367

February

What is Neratinib (ne-ra-ti-nib) and how does it work?

Guideline Norovirus Outbreak

Chapter 11 PREVENTING INFECTION. Elsevier items and derived items 2010 by Mosby, Inc. an affiliate of Elsevier Inc. All rights reserved

Radioiodine Therapy for Thyrotoxicosis (Hyperthyroidism)

What do I need to know about HIV and sex? What are my responsibilities and choices?

Parathyroid Scan with Contrast CT

Information and instruction for Home Helps caring for clients with indwelling urinary catheters

What is hepatitis? What is hepatitis A? How is it spread? What are the symptoms? How soon do symptoms appear? How is hepatitis A diagnosed?

F REQUENTLY A SKED Q UESTIONS

ORAL CHEMOTHERAPY EDUCATION

Hepatitis B. What Is Hepatitis? What Are The Two Stages Of Hepatitis? Published on: 5 Oct 2010

What is C difficile? (Clostridium difficile) Patient information leaflet

MRSA. (Methicillin-resistant Staphylococcus aureus) Patient & Family Guide.

Universal /Standard Precautions and Bloodborne Pathogens

Welcome to Your Reading Assignment

Health Advisory: Viral Gastrointestinal Illness in the Camp Setting

Breast Brachytherapy. Radiation Treatment. Permanent Seed Implant at the Tom Baker Cancer Centre

Transcription:

PATIENT EDUCATION patienteducation.osumc.edu Peptide Receptor Radionuclide Therapy (PRRT) Lu-177 What is a neuroendocrine tumor? Neuroendocrine cells are mainly found in your bowel, pancreas and lungs. These cells make hormones. A neuroendocrine tumor can happen when there is a change, or mutation, in one of your genes. This can cause your body to make too many neuroendocrine cells that begin to take over an area where normal tissue would grow. These tumors begin to make extra hormones and can cause problems, including carcinoid syndrome. What is Peptide Receptor Radionuclide Therapy (PRRT)? Peptide Receptor Radionuclide Therapy (PRRT) is a type of cancer therapy used to treat neuroendocrine tumors. Lutetium-177 (Lu-177) is a type of radioactive material used in PRRT. A hormone medicine, Octreotide, is mixed with a small amount of Lu-177 and placed into your blood. Once this medicine attaches to your neuroendocrine tumor, a high dose of radiation is given directly to your cancer cells. You will receive this treatment 4 times, 1 time every 8 weeks. What should I do to prepare for my care after treatment? It is important for you to know the difference between radioactive contamination and radiation exposure. Radioactive contamination happens when any amount of radioactive material is left behind on a surface that you have touched. Lu-177 stays in your body fluids for a period of time after your treatment. It is important to keep your body fluids cleaned up to keep others from coming in contact with any radioactive material from your treatment. This handout is for informational purposes only. Talk with your doctor or health care team if you have any questions about your care. May 11, 2018. The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

When you receive Lu-177, it will go into your blood and will be absorbed by neuroendocrine cells. Any Lu-177 that does not get absorbed will leave your body through your body fluids (urine, stool, sweat, saliva, vaginal secretions, semen and tears). Your urine will have the largest amount of Lu -177. Radiation exposure is the amount of radiation given off by your body after the Lu-177 treatment. This amount can only be measured by radiation detection equipment. When you are near other people, they are at risk for exposure to the radiation material. After you receive the Lu-177, your body will give off radiation. It is important to keep a safe distance between you and others for 1 day after each treatment, to lower the risk of radiation exposure. To keep your family, friends and co-workers safe, it is very important for you to make plans for your care after treatment. Before Your Treatment Before you start your treatment, it is important to talk with your doctor about all the medicines you take, including any vitamins or supplements, prescription medicines and over-the-counter medicines and remedies. Your doctor will tell you if you need to stop taking any medicines. You can eat and drink as normal before your treatment. Day of Treatment On the day of your treatment, you will check in at the Clinical Trials Unit (CTU) on the 5th floor of The James Cancer Hospital. You will meet with the radiation safety team to learn about radiation exposure precautions you must follow after your treatment. They will answer any questions you have about radiation and radiation safety. A nurse will take you to a treatment room. To lower the risk of radiation exposure, the floor and chair or bed in the treatment room will be covered with plastic. A nurse will place two intravenous (IV) catheters into your arms. IV catheters are long, thin, flexible tubes placed into vein to give you medicine. One IV will be used for your PRRT (Lut-177) and the other will be used to give you medicine to protect your kidneys from the radiation (amino acid infusion). You may also receive medicine to prevent nausea during and after your treatment.

If you have had a hard time with IVs being placed, tell your treatment team. They can have your IVs placed using an ultrasound. You will receive the amino acid infusion first. This will take 30 minutes. Next you will receive Lu-177. This will take 30 minutes. To decrease the risk of radiation exposure any visitors that are with you will need to leave the treatment room during this time. You will then receive more of the amino acid infusion. This will take about 4 hours. You should expect to spend a total of 6 hours in the CTU for each treatment. After Treatment A scan will be done 24 hours after your treatment to check if the Lu-177 attached to your tumor cells. What special precautions will I need to follow after my treatment? After your treatment, you will have small amounts of radioactive Lu-177 in all your body fluids and you will give off low levels of radiation. The farther away you stay and the less time you spend with others will reduce their risk of radiation exposure. It is important for you to follow these safety precautions to make sure you and those around you are safe after your Lu-177 treatment. Body Fluid Precautions Follow these precautions for 1 day after your treatment or as directed by your doctor Do not have close contact with anyone. This includes hugging, kissing or sexual activity of any type. Wash your hands often, use soap and warm water for at least 20 seconds. Double bag any items soiled with body fluids that can be thrown away. Keep the bagged items for a least 2 weeks before you put them in the regular trash can.

Latex or disposable gloves should be worn when you or someone else handles any of your body fluids. Wash your hands after you take the gloves off. When you use the toilet, it is important to flush at least 3 times after each use. Men should sit down to urinate. Any clothes or linens that come in contact with urine or feces should be washed right away. Wash these items separate from other laundry. Do not prepare food for others or share food with others. Use disposable plates and eating utensils. If you must use regular dishes, wash your dishes separately. Other Precautions for Women You will not be given Lu-177 treatment if you are pregnant. Do not get pregnant during your treatment and for 6 months after your treatment. Stop breastfeeding before you start your Lu-177 treatment. Do not breastfeed children during your treatment and for 6 weeks after your treatment. Other Precautions for Men Do not plan a pregnancy with your partner for 6 months after your treatment. Other Important Safety Precautions Drink plenty of fluids. If you are in the hospital or need emergency care, it is important to tell the health care team about your Lu-177 treatment. You should keep your treatment letter with you at all times and for at least 3 months after your treatment has ended. If you travel, it is important to keep your treatment letter with you at all times and for at least 3 months after your treatment has ended. If you have questions about radiation safety, call The Ohio State University Radiation Safety Department at (614) 561-7696.

What are the side effects of this treatment? PRRT with Lu-177 causes few problems. The following are side effects that may be caused by this treatment. Nausea and vomiting - your doctor will talk with you about medicines that can be ordered to help with this problem. Low blood cell counts - you will have weekly lab work to check your blood cell counts. This side effect can last up to 6 weeks. Fatigue and weakness - which may last for a week. What is the cost of Lu-177? It is important to check with your insurance company about what your plan covers before your Lu-177 treatment begins. To help cover the cost of your treatment, you will be given a Lu-177 Financial Assistance Form. Your health care team can review this form with you and help you fill it out. This form will be sent to AAA Patient Connect, a company who helps provide financial assistance for medical treatments. If you receive financial assistance, it may not cover the total cost. You may still need to cover some of the cost of the treatment. If you have questions about how to pay for your treatment, call The Ohio State University Wexner Medical Center Medication Assistance Program at (614) 366-7336. After the insurance pre-authorization is complete and you know if you will receive financial assistance, we will schedule your first treatment.